Fondazione Irccs Istituto Nazionale Dei Tumori

Milan, MI 20133

1 studies enrolling now · 9 studies all time

What they study most

Advanced Solid Tumor, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Genes, BRCA 1, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Locally Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors, Lymphoma, Melanoma, Metastatic Solid Tumors, Multiple Myeloma

Studies at this site

• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements — Recruiting now
• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma — Running, not enrolling
• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Running, not enrolling
• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC — Running, not enrolling
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — Running, not enrolling
• A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor — Completed
• PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors — Stopped early
• A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity — Running, not enrolling
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors — Stopped early